drugset
drugset / Trial / NCT01161186

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

NCT01161186 ↗

Phase 1 Completed 15 enrolled University of California, San Francisco Celgene Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.

Timeline

Start
2010-07
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 500 mg/m2 Oral
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Gemcitabine Small molecule 750 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 100 mg/m2 Intravenous
Subject Nab-paclitaxel Small molecule 150 mg/m2 Intravenous

Indications

pancreatic adenocarcinoma